Literature DB >> 22205225

Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice.

Chao-Sheng Lo1, Fang Liu, Yixuan Shi, Hasna Maachi, Isabelle Chenier, Nicolas Godin, Janos G Filep, Julie R Ingelfinger, Shao-Ling Zhang, John S D Chan.   

Abstract

We investigated the effects of dual renin-angiotensin system (RAS) blockade on angiotensin-converting enzyme-2 (Ace2) expression, hypertension, and renal proximal tubular cell (RPTC) apoptosis in type 1 diabetic Akita angiotensinogen (Agt)-transgenic (Tg) mice that specifically overexpress Agt in their RPTCs. Adult (11 wk old) male Akita and Akita Agt-Tg mice were treated with two RAS blockers (ANG II receptor type 1 blocker losartan, 30 mg·kg(-1)·day(-1)) and angiotensin-converting enzyme (ACE) inhibitor perindopril (4 mg·kg(-1)·day(-1)) in drinking water. Same-age non-Akita littermates and Agt-Tg mice served as controls. Blood pressure, blood glucose, and albuminuria were monitored weekly. The animals were euthanized at age 16 wk. The left kidneys were processed for immunohistochemistry and apoptosis studies. Renal proximal tubules were isolated from the right kidneys to assess gene and protein expression. Urinary ANG II and ANG 1-7 were quantified by ELISA. RAS blockade normalized renal Ace2 expression and urinary ANG 1-7 levels (both of which were low in untreated Akita and Akita Agt-Tg), prevented hypertension, albuminuria, tubulointerstitial fibrosis and tubular apoptosis, and inhibited profibrotic and proapoptotic gene expression in RPTCs of Akita and Akita Agt-Tg mice compared with non-Akita controls. Our results demonstrate the effectiveness of RAS blockade in preventing intrarenal RAS activation, hypertension, and nephropathy progression in diabetes and support the important role of intrarenal Ace2 expression in modulating hypertension and renal injury in diabetes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205225      PMCID: PMC3340935          DOI: 10.1152/ajprenal.00340.2011

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  46 in total

Review 1.  Angiotensin-(1-7) and the renin-angiotensin system.

Authors:  Robson A S Santos; Anderson J Ferreira
Journal:  Curr Opin Nephrol Hypertens       Date:  2007-03       Impact factor: 2.894

Review 2.  The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?

Authors:  R E Gilbert; M E Cooper
Journal:  Kidney Int       Date:  1999-11       Impact factor: 10.612

3.  Glomerulotubular junction abnormalities are associated with proteinuria in type 1 diabetes.

Authors:  Behzad Najafian; John T Crosson; Youngki Kim; Michael Mauer
Journal:  J Am Soc Nephrol       Date:  2006-04       Impact factor: 10.121

4.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Authors:  F N Ziyadeh; B B Hoffman; D C Han; M C Iglesias-De La Cruz; S W Hong; M Isono; S Chen; T A McGowan; K Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

5.  Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study.

Authors:  Caroline S Fox; Sean Coady; Paul D Sorlie; Ralph B D'Agostino; Michael J Pencina; Ramachandran S Vasan; James B Meigs; Daniel Levy; Peter J Savage
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

6.  A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.

Authors:  M Donoghue; F Hsieh; E Baronas; K Godbout; M Gosselin; N Stagliano; M Donovan; B Woolf; K Robison; R Jeyaseelan; R E Breitbart; S Acton
Journal:  Circ Res       Date:  2000-09-01       Impact factor: 17.367

7.  Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway.

Authors:  Vijay Koka; Xiao Ru Huang; Arthur C K Chung; Wansheng Wang; Luan D Truong; Hui Yao Lan
Journal:  Am J Pathol       Date:  2008-04-10       Impact factor: 4.307

8.  RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney.

Authors:  S Sachetelli; Q Liu; S-L Zhang; F Liu; T-J Hsieh; M-L Brezniceanu; D-F Guo; J G Filep; J R Ingelfinger; C D Sigmund; P Hamet; J S D Chan
Journal:  Kidney Int       Date:  2006-03       Impact factor: 10.612

9.  Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice.

Authors:  M-L Brezniceanu; F Liu; C-C Wei; S Tran; S Sachetelli; S-L Zhang; D-F Guo; J G Filep; J R Ingelfinger; J S D Chan
Journal:  Kidney Int       Date:  2007-03-07       Impact factor: 10.612

10.  Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy.

Authors:  Katalin Susztak; Emilio Ciccone; Peter McCue; Kumar Sharma; Erwin P Böttinger
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069

View more
  33 in total

1.  Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice.

Authors:  Esam S B Salem; Nadja Grobe; Khalid M Elased
Journal:  Am J Physiol Renal Physiol       Date:  2014-01-22

2.  Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes.

Authors:  Liliya M Yamaleyeva; Shea Gilliam-Davis; Igor Almeida; K Bridget Brosnihan; Sarah H Lindsey; Mark C Chappell
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-29

3.  Functional and molecular evidence for expression of the renin angiotensin system and ADAM17-mediated ACE2 shedding in COS7 cells.

Authors:  Nadja Grobe; Mauricio Di Fulvio; Nada Kashkari; Harshita Chodavarapu; Hari K Somineni; Richa Singh; Khalid M Elased
Journal:  Am J Physiol Cell Physiol       Date:  2015-03-04       Impact factor: 4.249

4.  Calcitriol regulates angiotensin-converting enzyme and angiotensin converting-enzyme 2 in diabetic kidney disease.

Authors:  Mei Lin; Ping Gao; Tianya Zhao; Lei He; Mengshi Li; Yaoyao Li; Hua Shui; Xiaoyan Wu
Journal:  Mol Biol Rep       Date:  2016-03-12       Impact factor: 2.316

Review 5.  Proximal tubule angiotensinogen modulation of arterial pressure.

Authors:  Nirupama Ramkumar; Donald E Kohan
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-01       Impact factor: 2.894

6.  Nrf2 Deficiency Upregulates Intrarenal Angiotensin-Converting Enzyme-2 and Angiotensin 1-7 Receptor Expression and Attenuates Hypertension and Nephropathy in Diabetic Mice.

Authors:  Shuiling Zhao; Anindya Ghosh; Chao-Sheng Lo; Isabelle Chenier; James W Scholey; Janos G Filep; Julie R Ingelfinger; Shao-Ling Zhang; John S D Chan
Journal:  Endocrinology       Date:  2018-02-01       Impact factor: 4.736

Review 7.  ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

Authors:  A C Simões e Silva; K D Silveira; A J Ferreira; M M Teixeira
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

8.  Heterogeneous nuclear ribonucleoproteins F and K mediate insulin inhibition of renal angiotensinogen gene expression and prevention of hypertension and kidney injury in diabetic mice.

Authors:  S Abdo; C-S Lo; I Chenier; A Shamsuyarova; J G Filep; J R Ingelfinger; S-L Zhang; J S D Chan
Journal:  Diabetologia       Date:  2013-04-23       Impact factor: 10.122

9.  Angiotensin-(1-7): A Novel Peptide to Treat Hypertension and Nephropathy in Diabetes?

Authors:  Ranjit Singh Padda; Yixuan Shi; Chao-Sheng Lo; Shao-Ling Zhang; John S D Chan
Journal:  J Diabetes Metab       Date:  2015-10-14

10.  Overexpression of catalase prevents hypertension and tubulointerstitial fibrosis and normalization of renal angiotensin-converting enzyme-2 expression in Akita mice.

Authors:  Yixuan Shi; Chao-Sheng Lo; Isabelle Chenier; Hasna Maachi; Janos G Filep; Julie R Ingelfinger; Shao-Ling Zhang; John S D Chan
Journal:  Am J Physiol Renal Physiol       Date:  2013-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.